Home » Topics » Conferences, BioWorld Science

Conferences, BioWorld Science
RSS

ETA antagonism with LU-135252 may provide novel antiischemic therapy

Aug. 28, 1998

Contrast agent from Nycomed Imaging proves useful for several applications

Aug. 28, 1998

AR-C69931MX; a novel P2T antagonist with platelet aggregation-inhibitory activity

Aug. 28, 1998

Glaxo Wellcome presents development candidate GW-311616A

Aug. 27, 1998

New agent for the prevention of osteoarthritis identified at Roche Bioscience

Aug. 27, 1998

Bristol-Myers Squibb program on beta3-adrenoceptor agonists outlined at ACS

Aug. 27, 1998

MMP inhibitors under investigation at Pharmacia & Upjohn

Aug. 27, 1998

News from the ACS: LTB4 antagonists for diagnostic use

Aug. 27, 1998

A-131701: a uroselective alpha-adrenergic agent for treatment of BPH

Aug. 27, 1998

GG-745: a 5alpha-reductase inhibitor with significant advantages over finasteride

Aug. 27, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...